Co-Diagnostics, Inc.
NASDAQ Capital MarketTotal Valuation
Co-Diagnostics, Inc. carries a market capitalization of 5.77M, placing it among publicly traded companies globally. Its enterprise value stands at -3.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.77M |
| Enterprise Value | -3.34M |
Share Statistics
Co-Diagnostics, Inc. currently has 3.60M shares outstanding.
| Shares Outstanding | 3.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.99, and the price-to-book ratio stands at -0.03.
| PE Ratio | N/A |
| PS Ratio | 3.99 |
| PB Ratio | -0.03 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | -0.10 |
| P/OCF Ratio | -0.10 |
Enterprise Valuation
| EV / Sales | 6.03 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Co-Diagnostics, Inc. maintains a current ratio of 2.28, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.28 |
| Quick Ratio | 1.94 |
| Debt / Equity | 12.66 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -126.56 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.41 |
Taxes
| Income Tax | -1.63M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Co-Diagnostics, Inc.'s stock has declined approximately -39.31925% over the past 52 weeks. The 50-day moving average sits at 2.56, while the 200-day moving average is 6.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -39.31925% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 6.63 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Co-Diagnostics, Inc. generated 718,166.00 in revenue and converted that into -48.50M in net income, yielding earnings per share of -31.49. EBITDA reached -30.86M, while operating income came in at -31.94M.
| Revenue | 718,166.00 |
| Gross Profit | 323,611.00 |
| Operating Income | -31.94M |
| Pretax Income | -50.13M |
| Net Income | -48.50M |
| EBITDA | -30.86M |
| EBIT | -31.94M |
| Earnings Per Share (EPS) | -31.49 |
Balance Sheet
Co-Diagnostics, Inc. holds 8.23M in cash and equivalents against 2.03M in total debt, resulting in a net debt position of -8.23M. Total book value stands at -89.44M, with working capital of 5.50M providing operational flexibility.
| Cash & Cash Equivalents | 8.23M |
| Total Debt | 2.03M |
| Net Debt | -8.23M |
| Equity (Book Value) | -89.44M |
| Book Value Per Share | -58.08 |
| Working Capital | 5.50M |
Cash Flow
Co-Diagnostics, Inc. produced -28.24M in operating cash flow over the past twelve months. After subtracting -750,151.00 in capital expenditures, free cash flow totaled -28.99M - equivalent to -18.82 per share.
| Operating Cash Flow | -28.24M |
| Capital Expenditures | -750,151.00 |
| Free Cash Flow | -28.99M |
| FCF Per Share | -18.82 |
Margins
Co-Diagnostics, Inc. operates with a gross margin of 45.06, reflecting its pricing power and cost economics. The operating margin of -4,447.41 and net profit margin of -6,753.69 provide insight into operational efficiency.
| Gross Margin | 45.06 |
| Operating Margin | -4,447.41 |
| Pretax Margin | -6,980.30 |
| Profit Margin | -6,753.69 |
| EBITDA Margin | -4,296.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -551.29 |
| FCF Yield | -959.61 |
Stock Splits
Co-Diagnostics, Inc.'s most recent stock split took place on January 2, 2026 with a 30:1 split ratio.
| Last Split Date | 1/2/2026 |
| Split Ratio | 30:1 |
Scores
Co-Diagnostics, Inc. posts an Altman Z-Score of -15.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.33 |